LFVN vs. ONCY, VACC, CMRX, BRNS, MIST, ANVS, PRPH, SPRO, YS, and QTTB
Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Oncolytics Biotech (ONCY), Vaccitech (VACC), Chimerix (CMRX), Barinthus Biotherapeutics (BRNS), Milestone Pharmaceuticals (MIST), Annovis Bio (ANVS), ProPhase Labs (PRPH), Spero Therapeutics (SPRO), YS Biopharma (YS), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
LifeVantage has a net margin of 1.75% compared to LifeVantage's net margin of 0.00%. Oncolytics Biotech's return on equity of 27.02% beat LifeVantage's return on equity.
LifeVantage received 68 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 77.82% of users gave LifeVantage an outperform vote while only 68.30% of users gave Oncolytics Biotech an outperform vote.
LifeVantage has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncolytics Biotech had 18 more articles in the media than LifeVantage. MarketBeat recorded 19 mentions for Oncolytics Biotech and 1 mentions for LifeVantage. Oncolytics Biotech's average media sentiment score of 1.94 beat LifeVantage's score of 0.33 indicating that LifeVantage is being referred to more favorably in the news media.
6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 35.3% of LifeVantage shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 6.8% of LifeVantage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oncolytics Biotech has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.
Oncolytics Biotech currently has a consensus target price of $4.00, indicating a potential upside of 260.36%. Given LifeVantage's higher probable upside, equities analysts clearly believe Oncolytics Biotech is more favorable than LifeVantage.
Summary
LifeVantage beats Oncolytics Biotech on 12 of the 16 factors compared between the two stocks.
Get LifeVantage News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LifeVantage Competitors List
Related Companies and Tools
